Completed PHASE2 INTERVENTIONAL NCT00491543

Evaluation of ALT-2074 in Subjects With Type-2 Diabetes, Haptoglobin Type 2-2 Genotype and Coronary Artery Disease

A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ALT 2074 in Subjects With Type 2 Diabetes Who Have a Haptoglobin Type 2-2 Genotype and Coronary Artery Disease

Sponsor: Synvista Therapeutics, Inc

Conditions Coronary Artery Disease Diabetes

Interventions ALT-2074

Updated 5 times since 2017 Last updated: Jul 1, 2008 Started: Jun 30, 2007 Completion: May 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00491543, this PHASE2 trial focuses on Coronary Artery Disease and Diabetes and remains completed. Sponsored by Synvista Therapeutics, Inc, it has been updated 5 times since 2007, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jun 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Synvista Therapeutics, Inc

Data source: Synvista Therapeutics, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States
• Cincinnati, United States